Best Practices in Antipsychotic Use for Parkinson’s Disease Psychosis (Archived CE Monograph)
This educational activity has expired. You will not be able to claim credit for this activity.
Activity Description and Purpose
Parkinson’s disease (PD) is a debilitating neurodegenerative condition that primarily affects movement but can also cause a host of “nonmotor” symptoms, including disrupted sleep, constipation, and even psychiatric effects such as depression and psychosis. Nonmotor symptoms of PD are increasingly recognized for their effect on function and quality of life, yet psychotic symptoms—including hallucinations and delusions—are often overlooked and undertreated. Parkinson’s disease psychosis (PDP) is estimated to occur in more than one-half of persons with PD and is now considered part of the neurodegenerative disease process for many of those with PD. Recognizing the signs and symptoms of PDP and training staff to use effective communication techniques to assess the cause of troublesome behaviors is crucial for the early detection and management of PDP. Otherwise, the disease can often worsen if untreated or undertreated. Although nonpharmacologic interventions can be effective in managing behaviors that are caused by unmet needs and may help with some aspects of PDP, pharmacologic treatment is often required to manage hallucinations or delusions in PD. When pharmacologic treatment is necessary, the choice of antipsychotic should consider both current guidance and evidence for safety and efficacy. This educational activity captures the proceedings of an expert roundtable discussion among faculty who specialize in the management of challenging issues in long-term care. The desired results of this activity are for long-term care clinicians to recognize psychosis as part of the disease process in PDP and treat symptoms effectively while maintaining safety and patient quality of life.
This educational activity is intended for National Association of Directors of Nursing Administration in Long Term Care (NADONA) members, including directors of nursing and nurse executives, and other long-term care providers caring for patients with Parkinson’s disease psychosis.
After completing this activity, participants will be better able to:
- Describe the signs and symptoms of Parkinson’s disease psychosis
- Integrate effective communication strategies into care for assessing symptoms of psychosis in patients with Parkinson’s disease
- Appraise individualized pharmacologic and nonpharmacologic management plans for long-term care residents with Parkinson’s disease psychosis
- Adapt management plans for patients with psychotic symptoms according to the latest guidance on appropriate use of antipsychotics
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Robin Arnicar, RN, has no relevant commercial relationships to disclose.
Cindy Fronning, RNC, has no relevant commercial relationships to disclose.
Dana Saffel, PharmD, is on the speakers’ bureau for ACADIA Pharmaceuticals Inc and is a consultant for ACADIA Pharmaceuticals Inc.
Nancy Tuders, RN-BC, has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
In support of improving patient care, this activity has been planned and implemented by MedEdicus LLC and NADONA. 1.5 Continuing education credits are provided by Terri Goodman & Associates. Terri Goodman & Associates is approved as a provider of nursing continuing professional development by the New Mexico Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 2020-08-AP.
Credit Designation Statement
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
Disclosure of Commercial Support
This continuing education activity is supported through an unrestricted educational grant from ACADIA Pharmaceuticals Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, NADONA, ACADIA Pharmaceuticals Inc, or The Director.
This CE activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 222